Chapter has secured a $100 million Series E round aimed at addressing Medicare “mismatches” affecting seniors, according to the latest financing coverage. The round was led by Generation Investment Management with participation from multiple venture and investment firms. While not a clinical-stage drug development update, the money signals continued venture capital interest in healthcare infrastructure and coverage-related solutions that can influence access to therapies and services. For biopharma operators, faster resolution of reimbursement mismatches can affect provider workflows and patient throughput. The funding also highlights that payer-driven barriers remain a persistent bottleneck in translating advanced therapies into real-world care at scale.